Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.
- DOI
- 10.1007/s40268-026-00535-y
- Published
- 2026 Mar
- Container
- Drugs in R&D
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40268-026-00535-y,
title = {Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.},
author = {Chu H and Xu G and Liu Y and Qian N and Li Y and Liu Y and Pan X and Gao X and Ou L and Lv J and Song H},
year = {2026},
journal = {Drugs in R\&D},
doi = {10.1007/s40268-026-00535-y},
url = {https://doi.org/10.1007/s40268-026-00535-y}
}RIS
TY - JOUR TI - Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile. AU - Chu H AU - Xu G AU - Liu Y AU - Qian N AU - Li Y AU - Liu Y AU - Pan X AU - Gao X AU - Ou L AU - Lv J AU - Song H PY - 2026 JO - Drugs in R&D DO - 10.1007/s40268-026-00535-y UR - https://doi.org/10.1007/s40268-026-00535-y ER -
APA
H, C., G, X., Y, L., N, Q., Y, L., Y, L., X, P., X, G., L, O., J, L., & H, S. (2026). Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.. Drugs in R&D. https://doi.org/10.1007/s40268-026-00535-y
Source records
- pubmed · retrieved 2026-09-26T17:07:43.527Z
- europe-pmc · retrieved 2026-09-26T17:07:43.546Z
- doaj · retrieved 2026-09-26T17:07:43.540Z